SFSIG
RVNC

San Francisco Sentry Investment Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

San Francisco Sentry Investment Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2,500
Closed -$48K – 464
2014
Q3 		$48K Hold
2,500
– – 0.02% 302
2014
Q2 		$85K Buy
+2,500
New +$78.3K 0.04% 254

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
NHG
NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

San Francisco Sentry Investment Group's RVNC Position: Q4 2014 in Review

San Francisco Sentry Investment Group sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2014, closing a stake of 2,500 shares — an estimated $48K sold.

San Francisco Sentry Investment Group first reported a position in RVNC in Q2 2014 and held it in 2 quarters. The position peaked at $85K in Q2 2014. 69 funds tracked by Wall St. Rank hold RVNC as of Q4 2014.

  • San Francisco Sentry Investment Group reported no remaining Revance Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
  • San Francisco Sentry Investment Group sold 2,500 Revance Therapeutics, Inc. shares in Q4 2014, an estimated $48K.
  • San Francisco Sentry Investment Group first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 2 quarters.
  • San Francisco Sentry Investment Group's Revance Therapeutics, Inc. position peaked at $85K in Q2 2014.
  • 69 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2014.

Based on San Francisco Sentry Investment Group's 13F filing for Q4 2014, filed 18 Feb 2015.